SCHEMBL4558064

SCHEMBL4558064

O=C(O)[C@@H]1Cc2ccccc2CN1C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.60
TAS1R1 Q7RTX1 1/20 0.60
TAS1R2 Q8TE23 1/20 0.60
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
GAA P10253 1/20 0.57
CFTR P13569 5/20 0.54
POLB P06746 3/20 0.52
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 1/20 0.49
PKM P14618 1/20 0.49
ACE P12821 2/20 0.48
MMP3 P08254 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
RECQL P46063 1/20 0.47
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27431292 0.91 NPC1 (0.55) TDP1L3MBTL1POLBCYP3A4CYP2C19
SCHEMBL6597524 0.83 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2TDP1MEN1
SCHEMBL4604495 0.82 F10 (0.59) TDP1L3MBTL1MEN1KMT2AGAA
SCHEMBL4111979 0.80 TDP1 (0.62) TDP1L3MBTL1MEN1KMT2AGAA
SCHEMBL6102700 0.80 DRD4 (0.56) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL13626502 0.79 LMNA (0.58) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL13626553 0.79 F10 (0.61) CFTR
SCHEMBL13626552 0.79 F10 (0.61) CFTR
SCHEMBL13626503 0.79 CFTR (0.56) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL13626514 0.78 LMNA (0.53) TAS1R3TAS1R1TAS1R2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612089-B2 Tetrahydroisoquinolines as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-03 US disclosed
US-20060160840-A1 N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160840-A1 N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample TFPI, F2, TFPI2 TAS1R3 2266/4885TAS1R1 2423/4885TAS1R2 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.